Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.

Clinical trial details

A PHASE I, OPEN-LABEL, DOSE FINDING STUDY OF NILK-2401, A BISPECIFIC CEACAM5 x CD47 ENGAGING ANTI-BODY, AS A SINGLE AGENT AND IN COMBINATION WITH ANTI-PD-1 ANTIBODY, IN PATIENTS WITH CEACAM5 EX-PRESSING SOLID CANCERS

Identifier

LCB-2401-001

Sponsor

LIGHTCHAIN BIOSCIENCE

Principal Investigator

JOSEP TABERNERO CATURLA

Service

Oncology

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Biespecific antibodies
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: CEACAM5 pos
Biomarker criteria: Mandatory
Prescreening: Local
Additional study population requirements: NILK-2041 is the bispecific antibody targeting CD47 and a Tumor-Associated Antigen (TAA) Inclusion criteria: solid malignancies expressing CEA-CAM5

Drug details

Arm A: NILK-2401
Arm B: NILK-2401 + Pembrolizumab

Links

Clinical Trials GOV (NCT identifier): NL
EU Clinical Trials Register (eudraCT Identifier): Not applicable